Foot-and-mouth disease (FMD) is an acute and febrile infectious disease, which can cause great economic losses. Virus-like particles (VLPs) as an advantageous antigen can induce significant specific immune response. To improve immunity of VLPs, especially, make it induce persistent immune response, the hollow mesoporous silica nanoparticles (HMSNs) as a potential nano-adjuvant were synthesized and loaded the FMD virus (FMDV) VLPs. They were injected into guinea pigs and the specific immune response was detected. The results confirmed that HMSNs/VLPs can induce persistent humoral immunity with high-level antibody titer for more than three months. HMSNs also improve the T-lymphocyte proliferation and IFN-γ induced by FMDV VLPs, and provides the ideal protection against FMDV challenge. These consequences indicated that HMSNs were good protein delivery vehicle and potential nano-adjuvant of vaccines.
safer and more efficient adjuvants than those currently available can address the shortcomings of new vaccines. 9, 10 Nanoparticles can be designed for targeted antigen delivery to immune cells and stimulate the immune response to promote antigen immunogenicity. Thus, they are usually applied for developing nanovaccines and drug carriers. Nanoadjuvants are fabricated from nanosized particle materials. Nanoadjuvants exhibit strong adsorptive abilities, good slow-release function, and effective targeting and thermal stability. 11 At present, numerous nanoadjuvants have been developed. These materials include mesoporous silica nanoparticles, liposomes, calcium phosphate, aluminum hydroxide, polylactic-co-glycolic acid, and polylactic acid. [12] [13] [14] Hollow mesoporous silica nanoparticles (HMSNs), as drug delivery vehicles, possess relatively large surface areas, adjustable pore sizes, high surface paintability, controlled release capability, and good thermal stability. These properties are suitable for an ideal gene/drug delivery vehicle. [15] [16] [17] In this study, specific and persistent immune responses were 
| MATERIALS AND METHODS

| Synthesis and characterization of HMSNs
The HMSNs were synthesized using a sol-gel/emulsion (oil-in-water/ ethanol) method. 15, 18 First, 42 mL of ethanol, 79.5 mL of H 2 O, 1.5 mL of tetraethoxysilane (Aladdin, Shanghai, China), and 0.24 g of hexadecyltrimethylammonium bromide (YW, Wuhan, China) were mixed and stirred continuously. Then, 1.5 mL of ammonium solution (25 wt% NH 3 in water) was added, and the mixture was shaken or stirred (10 000 rpm) for 6 hours and stored for 24 hours at room temperature. Afterward, the HMSNs were washed several times with deionized water and ethanol and centrifuged at 8000 to 10 000 rpm for 15 to 20 minutes. The final product was calcined in air at 200°C for 6 hours and then at 600°C for 6 hours.
The morphological characteristics of the HMSNs were detected by dynamic light scattering (DLS; Malvern Instruments Ltd, Worcestershire, UK) and transmission electron microscopy (TEM). For DLS, the incident angle was 90°, and the incident wavelength of the laser was 633 nm. Each sample was measured three times at room temperature, and the average particle diameter was expressed as mean ± standard deviation (SD). TEM samples were prepared by dipping a drop of the solution onto carbonfilm-coated copper grids and staining with phosphotungstic acid. Then, a JEOL electron microscope (Tokyo, Japan) was used to observe the samples at an acceleration voltage of 100 kV. The Barrett-JoynerHalenda (BJH) method was applied to detect the total pore volume and pore diameter of HMSNs. The surface area of HMSNs was obtained using the Brunauer-Emmett-Teller (BET) method. 19 
| Assembly and detection of VLPs
The FMDV VLPs were produced and detected as described previously. 8, 20 The SUMO (Smt3) gene and FMDV capsid proteins VP0, VP1, and VP3 genes were subcloned into pET-28a, and then the recombinant plasmids were transformed into Escherichia coli BL21 (DE3). The transformed E. coli was cultivated at 37°C in Lysogeny broth medium and induced by isopropyl β-D-1-thiogalactopyranoside and then the fusion proteins were eluted with Buffer A (500 mM NaCl, 5%
glycerinum, 200 mM Tris-HCl, 1‰ Triton-X100, and 500 mM imidazole, pH 8.0). The SUMO-tag of fusion proteins was cleaved by SUMO protease and the FMDV capsid proteins VP0, VP1, and VP3 can selfassemble into VLPs in the buffer B (400 mM Tris-HCl, 250 mM NaCl, 1 mM CaCl 2 , and 1 mM dithiothreitol, pH 8.0) for 24 hours at 4°C. Then, the samples were centrifuged by sucrose gradient ultracentrifugation method, and the fraction was used for dynamic light scattering instrument (DLS) and transmission electron microscope (TEM).
| VLP adsorption of HMSNs
VLPs were adsorbed to HMSNs as described previously. 
| Size of the HMSNs/VLPs mixture
The size of the HMSNs/VLPs mixture was detected by DLS (Malvern Instruments Ltd). HMSNs (2 mg) was dispersed into PBS (1 mL) to obtain the final concentration 2 mg/mL. Then 0.25 mL HMSNs(2 mg/ mL) was mixed with 0.25 mL VLPs (800 μg/mL).
| Release kinetics of HMSNs
HMSNs/VLPs were suspended in PBS (pH 7.0), and the solution was maintained at 37°C. At different time points, samples were obtained for centrifugation (10 000 rpm, 5 minutes). The amount of protein released by HMSNs was detected with a Bradford protein assay kit (Beyotime Biotechnology, Shanghai, China).
| Animal immunization and challenge protocols
Guinea pigs (300-400 g) were purchased from the Lanzhou Veterinary Research Institute and raised in isolation cages. These animals were then cared for in accordance with the regulations of the Animal
Research Ethics Board of Lanzhou Veterinary Research Institute, CAAS, China. The guinea pigs were randomized into six groups and immunized as described in Table 1 . The animals were each intramuscularly immunized in the tibialis cranialis muscle of both rear legs, and serum samples were gathered every two weeks from the heart of each guinea pig. 21, 22 Preexperiment confirmed that the challenge viral dose and 50% infectious dose for the guinea pigs were 0.2 and 10-6.5/0.2 mL, respectively. Then, 0.2 mL aliquots of homologous live virus solution diluted from 10 to 6.5 were subcutaneously and intradermally injected into the interdigital skin of each left back leg of guinea pigs at 14 weeks. The guinea pigs were observed for seven days continuously. 23, 24 The lesion appearing only on the left back leg was considered to as an indicator of partial protection, on both back soles as an indicator of no protection and no lesion on the back as an indicator of total protection.
| Enzyme-linked immunosorbent assay
Serum samples collected weekly from the guinea pigs were evaluated by enzyme-linked immunosorbent assay (ELISA). Initially, a 96-well ELISA microplate (Corning Incorporated, Corning, ME) was coated with 100 µL of FMDV 146S antigen in 0.05 M of NaHCO 3 coating buffer (pH 9.6) and incubated at 4°C overnight. After washing with phosphate buffered saline with Tween-20 (PBST) three times, the microplate was blocked with 120 µL of PBST containing 1% bovine serum albumin for 1 hour at 37°C. Then, 100 µL of diluted serum (1:32) with PBST was incubated for 1 hour at 37°C, washed three times with PBST, and then patted dry. Afterward, 100 µL of HRP-labeled rabbit anti-guinea pig IgG (Sigma-Aldrich, St. Louis, MO) was incubated as described above, followed by incubation with 100 µL of O-phenylenediamine/hydrogen peroxide (H 2 O 2 ) for 15 minutes at 37°C. The color reaction was stopped with 100 µL of 2 N H 2 SO 4 , and the optical density (OD) value was read using an ELISA reader (Bio-Rad, CA, USA) at 490 nm.
| T-lymphocyte proliferation assay
Spleens were collected from immunized guinea pigs, and then spleen cells were resuspended in RPMI 1640 medium. Lymphocyte separation medium (Sangon, China) was added, and the mixture was centrifuged at 1000 to 2000 rpm for 5 minutes. A straw was used to carefully extract the lymphocyte layer into the centrifuge tube, and then the lymphocytes were washed three times with RPMI 1640 medium. T-lymphocytes in 96-well plates (5 × 10 6 cells per well) were added to 100 µL of 50 μg/mL
ConA, 150 μg/mL ConA, and RPMI 1640 and incubated at 37°C under 5% CO2 for 68 hours. Next, 3-(4,5-dimethylthiazol-2yl)-3,5-diphenyltetrazolium bromide (MTT)/PMS mixture was added to each well, and the mixture was incubated at 37°C under 5% CO2 for 4 hours. The OD value was measured at 490 nm, and the stimulus index was calculated to reveal the level of T-lymphocyte proliferation.
| Detection of IFN-γ
The guinea pig IFN-γ levels in serum samples were determined by using a guinea pig IFN-γ ELISA kit (Ziker, Shenzhen, China) in accordance with the manufacturer's instructions. Initially, BSA was diluted to 9, 6, 3, 1.5, and 0.75 mmol/L and added to an ELISA plate (50 µL per well). Then, serum samples were diluted (1:5) and added to each well (50 µL). Measurements were performed in duplicate, and the OD450 was attained using an ELISA reader.
| Statistical analysis
Results among groups were presented as means and SDs; P < 0.05 was regarded as statistically significant. Statistical analysis was performed with GraphPad Prism (Version 5.0). Kruskal-Wallis H test was then used to evaluate specific and neutral antibody immune responses. Significant differences in T-lymphocyte immune responses among groups were determined using the Student t test.
3 | RESULTS
| Characterization of HMSNs
HMSNs were uniformly spherical particles ( Figure 1A and 1B), with an average spherical diameter of approximately 400 nm ( Figure 3C ).
The HMSN surface area was 1035.73 m 2 /g, which was obtained using the BET method ( Figure 1C 
| Determination of FMDV VLPs
After the assembly of FMDV VLPs in the assembly buffer, the product was filtered, and the product's molecular size was determined by DLS. The products were then negatively stained and HMSNs also exhibited a good ability to release proteins slowly ( Figure 3D ).
| Specific antibody in guinea pigs
To evaluate the adjuvant effect of HMSNs, the specific antibody Table 2 shows that all the guinea pigs were infected in the groups Thirty guinea pigs were randomized into six groups of five animals each. Each " − " or " + " symbol means one of guinea pig; " − " is a guinea pig that no lesion on the back legs; " + " is a guinea pig that the lesion appearing only on the left back sole or both back soles. Protection rates (%) = number of total protected guinea pigs per group/total number of guinea pigs per group × 100%. This result may be dependent on the large surface area of HMSNs and the high-density charge distribution on the VLPs surface. Thus, the HMSNs dosage is greatly decreased as vaccine adjuvant.
| Protective test against FMDV in guinea pigs
The immune response level can be reflected by specific antibody titers. 33 Release kinetics assay showed that VLPs can be released in a 
| CONCLUSIONS
In conclusion, HMSNs can be used as delivery vehicle and adjuvant in VLP vaccine development. These particles not only help the antigen to be engulfed by phagocytosis but also retard antigen release to achieve a sustained immune response. However, although the amount of HMSNs used as vaccine adjuvant was significantly reduced, the biological residue requires further study. 
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